<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02479321</url>
  </required_header>
  <id_info>
    <org_study_id>CEIC 15/03</org_study_id>
    <nct_id>NCT02479321</nct_id>
  </id_info>
  <brief_title>Goal Directed Hemodynamic Therapy Based on Noninvasive Monitoring in Patients With Hip Fracture</brief_title>
  <official_title>Efficacy of Goal Directed Hemodynamic Therapy Based on Noninvasive Monitoring to Reduce Perioperative Complications in Patients With Hip Fracture</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Juan-Víctor Lorente, MD, PhD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Althaia Xarxa Assistencial Universitària de Manresa</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Crude incidence rate in Spain of hip fracture in people over 65 years was 511 cases per&#xD;
      100,000 in 2002. About 30% of patients die in the first year. Cardiocirculatory complications&#xD;
      during and after surgery partly explain this high morbidity and mortality. Most patients are&#xD;
      frail and with multicomorbidity. Goal-Directed Hemodynamic Therapy (GDT) based on noninvasive&#xD;
      continuous monitoring of blood pressure, heart rate, oxygen saturation, cardiac output,&#xD;
      cardiac index, stroke volume and stroke volume index can reduce perioperative complications&#xD;
      and improve survival. The objective of our study is to assess the efficacy of a goal-directed&#xD;
      hemodynamic therapy in reducing perioperative complications. Patients and Methods:&#xD;
      non-randomized intervention study with a historical control and 1-year follow-up. Patients&#xD;
      older than 64 years with non-traumatic hip fracture requiring surgical intervention. In the&#xD;
      control group standard care was performed based on non-invasive, intermittent arterial&#xD;
      pressure measurement, obtained every 5 minutes, continuous heart rate, and oxygen saturation.&#xD;
      In the intervention group GDT based on noninvasive monitoring will be performed. The main&#xD;
      outcome will be the percentage of patients with perioperative complications. Secondary&#xD;
      outcomes: LOS and survival at 12 months of surgery.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2015</start_date>
  <completion_date type="Actual">February 2019</completion_date>
  <primary_completion_date type="Actual">February 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intraoperative complications</measure>
    <time_frame>Intraoperative period</time_frame>
    <description>Cardiocirculatory: haemodynamic instability and cardiac arrhytmias</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Postoperative complications</measure>
    <time_frame>Patients will be followed for the duration of hospital stay, an expected median of 11 days</time_frame>
    <description>Cardiocirculatory, respiratory, renal, and infectious</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hospital stay</measure>
    <time_frame>Patients will be followed for the duration of hospital stay, an expected median of 11 days</time_frame>
    <description>Length of hospital stay (days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>One-year survival</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">568</enrollment>
  <condition>Hip Fractures</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Hemodynamic optimization according to the standards of perioperative monitoring of our center. In the intraoperative period hemodynamic monitoring will be done by management of blood pressure, heart rate and oxygen saturation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GDT noninvasive monitoring group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GDT based on noninvasive monitoring System ClearSight® and Platform EV Clinic 1000®</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>GDT based on noninvasive monitoring</intervention_name>
    <description>Before entering the operating room, hemodynamic optimization start by optimizing preload with Fluid Challenge according to evidence-based GDT protocols. Once stabilized the cardiovascular system after induction of anesthesia, hemodynamic optimization continue with Mini Fluid Challenge.&#xD;
In the intraoperative period, hemodynamic optimization is based on maintaining systolic blood pressure and stroke volume. A Mini Fluid Challenge is administered to patients who respond to volume or a vasoactive drug according cardiac index for non-responders.</description>
    <arm_group_label>GDT noninvasive monitoring group</arm_group_label>
    <other_name>Intraoperative Goal-Directed Hemodynamic Therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>System ClearSight® and Platform EV Clinic 1000®</intervention_name>
    <description>Hemodynamic control is held by non-invasive continuous monitoring techniques (system ClearSight® and Platform EV Clinic 1000®). Monitored variables: blood pressure, heart rate, oxygen saturation, cardiac output, cardiac index, stroke volume and stroke volume index.</description>
    <arm_group_label>GDT noninvasive monitoring group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Hip fracture that require surgical treatment&#xD;
&#xD;
          -  Agree to participate and sign informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pathological or traffic related fractures&#xD;
&#xD;
          -  Anesthetic contraindication for surgery&#xD;
&#xD;
          -  Refractures&#xD;
&#xD;
          -  Contraindication for hemodynamic monitoring&#xD;
&#xD;
          -  Physiocal less than 30 after 7 minutes&#xD;
&#xD;
          -  Psychomotor agitation that prevents hemodynamic monitoring&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joan Bosch Sabater, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Althaia Xarxa Assistencial Universitària de Manresa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francesca Reguant Corominas, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Althaia Xarxa Assistencial Universitària de Manresa</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Althaia Xarxa Assistencial Universitària de Manresa</name>
      <address>
        <city>Manresa</city>
        <state>Barcelona</state>
        <zip>08243</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>June 15, 2015</study_first_submitted>
  <study_first_submitted_qc>June 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2015</study_first_posted>
  <last_update_submitted>May 26, 2021</last_update_submitted>
  <last_update_submitted_qc>May 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Althaia Xarxa Assistencial Universitària de Manresa</investigator_affiliation>
    <investigator_full_name>Juan-Víctor Lorente, MD, PhD</investigator_full_name>
    <investigator_title>Medical Doctor</investigator_title>
  </responsible_party>
  <keyword>Fluid therapy</keyword>
  <keyword>Aged</keyword>
  <keyword>Perioperative complications</keyword>
  <keyword>Survival</keyword>
  <keyword>Intraoperative Goal Directed Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fractures, Bone</mesh_term>
    <mesh_term>Hip Fractures</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

